NEWS

2021
 
  • Fair Pricing Coalition Welcomes Approval Of Two-Month HIV Prevention Shot; Denounces ViiV Healthcare’s Exorbitant, Unsustainable Pricing

2019 
 
  • Fair pricing Coalition Urges Full Hearing of Legal Claims in Staley v. Gilead​
     

  • Fair Pricing Coalition Welcomes Approval of ViiV’s Combination Tablet Dovato

​

2018

​​

  • Fair Pricing Coalition Welcomes Approval of ViiV’sFair Pricing Coalition Pleased with Steps by Gilead to Increase Access to PrEP, but More Actions Needed
     

  • Fair Pricing Coalition Disappointed at Launch Price of Janssen’s Protease Inhibitor-based Single-tablet Regimen Symtuza
     

  • Fair Pricing Coalition Welcomes U.S. Launches of Mylan’s Tenofovir and Lamivudine Coformulation (Cimduo) and Efavirenz-based Single Tablet Regimens
     

  • Letter to Gilead Sciences Opposing Unethical Patient Assistance Program Policy for Truvada for Post-exposure Prophylaxis

​

2017

​​

  • FPC Welcomes FDA Approval of AbbVie’s New Pangenotypic HCV Combination Mavyret
     

  • Health Affairs Blog Post Highlights Fair Pricing Coalition Recommendations to Modernize and Strengthen Existing Laws to Control Drug Costs
     

  • Fair Pricing Coalition Troubled by Unjustified 2017 Drug Price Increases by HIV Pharmaceutical Manufacturers

​

2016

​

  • FPC Releases New Report Urging Modernization of Existing Laws to Rein in Drug Pricing
     

  • Open Letter to Manufacturers of HIV and Hepatitis Medications Opposing 2017 Price Increases

​

​

  • HOME

  • ABOUT US

  • MISSION

  • PAP & COPAY ASSISTANCE PROGRAMS

  • NEWS

    • Apretude PrEP
  • CONTACT

  • More

    Use tab to navigate through the menu items.
    • Twitter Social Icon
    WHO WE ARE

    The Fair Pricing Coalition (FPC) is an ad hoc group of activists who advocate with the pharmaceutical industry regarding the price of HIV and hepatitis drugs